JP Morgan Downgrades Sotera Health to Underweight, Announces $17 Price Target
JP Morgan analyst Casey Woodring downgrades Sotera Health (NASDAQ:SHC) from Neutral to Underweight and announces $17 price target.
Stocks · News reference
Sotera Health Raises FY2026 Adj EPS Guidance from $0.93-$1.01 to $0.95-$1.01 vs $0.97 Est; Raises FY2026 Sales Guidance from $1.233B-$1.251B to $1.236B-$1.254B vs $1.241B Est
Sotera Health (NASDAQ:SHC) raises FY2026 Adj EPS guidance from $0.93-$1.01 to $0.95-$1.01 vs $0.97 analyst estimate. Raises FY2026 sales outlook from $1.233 billion-$1.251 billion to $1.236 billion-$1.254 billion vs
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Transcript: Sotera Health Q2 2026 Earnings Conference Call
Sotera Health (NASDAQ:SHC) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
8-K filing — Sotera Health Co (SHC)
Filed: 2026-08-14 AccNo: 0001822479-26-000050 Size: 141 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Citigroup Maintains Buy on Sotera Health, Raises Price Target to $25
Citigroup analyst Brendan Digan maintains Sotera Health (NASDAQ:SHC) with a Buy and raises the price target from $23 to $25.